Strides Pharma names Nandini Matiyani Global Head of HR

Strides Pharma Science has appointed Nandini Matiyani as Executive Vice President and Global Head of Human Resources, strengthening the company’s leadership bench as it scales its global operations.

In a post on LinkedIn, Matiyani said she was “embarking on a new journey” with Strides and will lead the global HR function across the pharmaceutical group’s international footprint. She thanked Chairman Arun Kumar, Managing Director and Group CEO Badri Srinivasan, and the board for their confidence in her appointment.

Matiyani brings more than 20 years of experience in people strategy, cultural transformation and HR leadership across multinational and publicly listed organisations. She said her focus at Strides will be on strengthening capabilities, reinforcing culture and supporting the company’s ambition to deliver “better and fairer healthcare” through agility, innovation and meaningful people practices.

Strides, established in 1990 and headquartered in Bengaluru, operates in more than 100 countries, supplying regulated markets, donor-funded channels and its “in Africa for Africa” business. The company manufactures complex pharmaceutical products from sites in India, Italy, Kenya and the United States.

Matiyani said she looks forward to working with teams across geographies to build talent strength and organisational capacity as Strides accelerates its global agenda. Her appointment underscores the company’s focus on leadership development and culture building as it competes in highly regulated and cost-sensitive markets.

The company has not announced further organisational changes, but the expanded HR leadership role signals a sharper emphasis on people systems and capability building as Strides targets growth across key markets.

Related Posts

Odisha Receives Investment Commitments Worth ₹7,043 Cr in Pharma & Medtech

Odisha has received investment commitments worth ₹7,043 crore across the pharmaceutical and medical technology sectors, marking a major step in strengthening the state’s position as an emerging healthcare manufacturing hub.…

Cough Syrup Racket Busted: Kingpin Shubham Jaiswal skips ED summons; Here’s what happens next

Mastermind of India’s massive codeine cough syrup racket skips ED summons- what’s next for Shubham Jaiswal? With arrest warrants, Red Corner Notices, and cross-border drug links, the investigation could expose…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Odisha Receives Investment Commitments Worth ₹7,043 Cr in Pharma & Medtech

Odisha Receives Investment Commitments Worth ₹7,043 Cr in Pharma & Medtech

Cough Syrup Racket Busted: Kingpin Shubham Jaiswal skips ED summons; Here’s what happens next

Cough Syrup Racket Busted: Kingpin Shubham Jaiswal skips ED summons; Here’s what happens next

Senores Pharmaceuticals to Acquire Apnar Pharma at Enterprise Value of ₹91 Crore

Senores Pharmaceuticals to Acquire Apnar Pharma at Enterprise Value of ₹91 Crore

Aytu BioPharma launches depression drug EXXUA in U.S. market

Aytu BioPharma launches depression drug EXXUA in U.S. market

Delhi govt carries out 27 raids against fake medicine

Delhi govt carries out 27 raids against fake medicine

Odisha Pharma Summit 2025 to Explore Opportunities in Pharmaceutical Sector on December 16

Odisha Pharma Summit 2025 to Explore Opportunities in Pharmaceutical Sector on December 16